156 related articles for article (PubMed ID: 17374756)
1. Reduction of the infectivity of hepatitis C virus pseudoparticles by incorporation of misfolded glycoproteins induced by glucosidase inhibitors.
Chapel C; Garcia C; Bartosch B; Roingeard P; Zitzmann N; Cosset FL; Dubuisson J; Dwek RA; Trépo C; Zoulim F; Durantel D
J Gen Virol; 2007 Apr; 88(Pt 4):1133-1143. PubMed ID: 17374756
[TBL] [Abstract][Full Text] [Related]
2. Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: implications for the development of broad spectrum anti-hepatitis virus agents.
Zitzmann N; Mehta AS; Carrouée S; Butters TD; Platt FM; McCauley J; Blumberg BS; Dwek RA; Block TM
Proc Natl Acad Sci U S A; 1999 Oct; 96(21):11878-82. PubMed ID: 10518544
[TBL] [Abstract][Full Text] [Related]
3. Antiviral effect of alpha-glucosidase inhibitors on viral morphogenesis and binding properties of hepatitis C virus-like particles.
Chapel C; Garcia C; Roingeard P; Zitzmann N; Dubuisson J; Dwek RA; Trépo C; Zoulim F; Durantel D
J Gen Virol; 2006 Apr; 87(Pt 4):861-871. PubMed ID: 16528036
[TBL] [Abstract][Full Text] [Related]
4. Novel imino sugar α-glucosidase inhibitors as antiviral compounds.
Howe JD; Smith N; Lee MJ; Ardes-Guisot N; Vauzeilles B; Désiré J; Baron A; Blériot Y; Sollogoub M; Alonzi DS; Butters TD
Bioorg Med Chem; 2013 Aug; 21(16):4831-8. PubMed ID: 23582447
[TBL] [Abstract][Full Text] [Related]
5. Antiviral effect of N-butyldeoxynojirimycin against bovine viral diarrhea virus correlates with misfolding of E2 envelope proteins and impairment of their association into E1-E2 heterodimers.
Branza-Nichita N; Durantel D; Carrouée-Durantel S; Dwek RA; Zitzmann N
J Virol; 2001 Apr; 75(8):3527-36. PubMed ID: 11264342
[TBL] [Abstract][Full Text] [Related]
6. Study of the mechanism of antiviral action of iminosugar derivatives against bovine viral diarrhea virus.
Durantel D; Branza-Nichita N; Carrouée-Durantel S; Butters TD; Dwek RA; Zitzmann N
J Virol; 2001 Oct; 75(19):8987-98. PubMed ID: 11533162
[TBL] [Abstract][Full Text] [Related]
7. [Affect of deoxynojirimycin derivatives on hepatitis C virus morphogenesis].
Timokhova AV; Bakinovskiĭ LV; Zinin AI; Popenko VI; Ivanov AV; Rubtsov PM; Kochetkov SN; Belzhelarskaia SN
Mol Biol (Mosk); 2012; 46(4):644-53. PubMed ID: 23113354
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of host ER glucosidase activity prevents Golgi processing of virion-associated bovine viral diarrhea virus E2 glycoproteins and reduces infectivity of secreted virions.
Jordan R; Nikolaeva OV; Wang L; Conyers B; Mehta A; Dwek RA; Block TM
Virology; 2002 Mar; 295(1):10-9. PubMed ID: 12033761
[TBL] [Abstract][Full Text] [Related]
9. Replication-competent recombinant vesicular stomatitis virus encoding hepatitis C virus envelope proteins.
Tani H; Komoda Y; Matsuo E; Suzuki K; Hamamoto I; Yamashita T; Moriishi K; Fujiyama K; Kanto T; Hayashi N; Owsianka A; Patel AH; Whitt MA; Matsuura Y
J Virol; 2007 Aug; 81(16):8601-12. PubMed ID: 17553880
[TBL] [Abstract][Full Text] [Related]
10. Treatment of hepatitis B virus-infected cells with alpha-glucosidase inhibitors results in production of virions with altered molecular composition and infectivity.
Lazar C; Durantel D; Macovei A; Zitzmann N; Zoulim F; Dwek RA; Branza-Nichita N
Antiviral Res; 2007 Oct; 76(1):30-7. PubMed ID: 17548120
[TBL] [Abstract][Full Text] [Related]
11. Optimized cell systems for the investigation of hepatitis C virus E1E2 glycoproteins.
Kalemera MD; Capella-Pujol J; Chumbe A; Underwood A; Bull RA; Schinkel J; Sliepen K; Grove J
J Gen Virol; 2021 Jan; 102(1):. PubMed ID: 33147126
[TBL] [Abstract][Full Text] [Related]
12. Action of celgosivir (6 O-butanoyl castanospermine) against the pestivirus BVDV: implications for the treatment of hepatitis C.
Whitby K; Taylor D; Patel D; Ahmed P; Tyms AS
Antivir Chem Chemother; 2004 May; 15(3):141-51. PubMed ID: 15266896
[TBL] [Abstract][Full Text] [Related]
13. Inhibitors of endoplasmic reticulum alpha-glucosidases potently suppress hepatitis C virus virion assembly and release.
Qu X; Pan X; Weidner J; Yu W; Alonzi D; Xu X; Butters T; Block T; Guo JT; Chang J
Antimicrob Agents Chemother; 2011 Mar; 55(3):1036-44. PubMed ID: 21173177
[TBL] [Abstract][Full Text] [Related]
14. Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans.
Helle F; Wychowski C; Vu-Dac N; Gustafson KR; Voisset C; Dubuisson J
J Biol Chem; 2006 Sep; 281(35):25177-83. PubMed ID: 16809348
[TBL] [Abstract][Full Text] [Related]
15. Role of oligosaccharides in the processing and maturation of envelope glycoproteins of human immunodeficiency virus type 1.
Pal R; Hoke GM; Sarngadharan MG
Proc Natl Acad Sci U S A; 1989 May; 86(9):3384-8. PubMed ID: 2541446
[TBL] [Abstract][Full Text] [Related]
16. Assembly of functional hepatitis C virus glycoproteins on infectious pseudoparticles occurs intracellularly and requires concomitant incorporation of E1 and E2 glycoproteins.
Sandrin V; Boulanger P; Penin F; Granier C; Cosset FL; Bartosch B
J Gen Virol; 2005 Dec; 86(Pt 12):3189-3199. PubMed ID: 16298963
[TBL] [Abstract][Full Text] [Related]
17. Role of N-linked glycans in the functions of hepatitis C virus envelope proteins incorporated into infectious virions.
Helle F; Vieyres G; Elkrief L; Popescu CI; Wychowski C; Descamps V; Castelain S; Roingeard P; Duverlie G; Dubuisson J
J Virol; 2010 Nov; 84(22):11905-15. PubMed ID: 20844034
[TBL] [Abstract][Full Text] [Related]
18. The combination of interferon alpha-2b and n-butyl deoxynojirimycin has a greater than additive antiviral effect upon production of infectious bovine viral diarrhea virus (BVDV) in vitro: implications for hepatitis C virus (HCV) therapy.
Ouzounov S; Mehta A; Dwek RA; Block TM; Jordan R
Antiviral Res; 2002 Sep; 55(3):425-35. PubMed ID: 12206880
[TBL] [Abstract][Full Text] [Related]
19. Mutational analysis of the hepatitis C virus E1 glycoprotein in retroviral pseudoparticles and cell-culture-derived H77/JFH1 chimeric infectious virus particles.
Russell RS; Kawaguchi K; Meunier JC; Takikawa S; Faulk K; Bukh J; Purcell RH; Emerson SU
J Viral Hepat; 2009 Sep; 16(9):621-32. PubMed ID: 19302336
[TBL] [Abstract][Full Text] [Related]
20. Berberine inhibits hepatitis C virus entry by targeting the viral E2 glycoprotein.
Hung TC; Jassey A; Liu CH; Lin CJ; Lin CC; Wong SH; Wang JY; Yen MH; Lin LT
Phytomedicine; 2019 Feb; 53():62-69. PubMed ID: 30668413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
